

Resource Summary Report

Generated by [RRID](#) on Aug 29, 2026

HuH-6

RRID:CVCL_4381

Type: Cell Line

Proper Citation

RRID:CVCL_4381

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_4381

Proper Citation: RRID:CVCL_4381

Description: Cell line HuH-6 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Hepatoblastoma

Defining Citation: [PMID:57894](#), [PMID:8389256](#), [PMID:9359923](#), [PMID:9671767](#), [PMID:15767549](#), [PMID:20937217](#), [PMID:22460905](#), [PMID:23505090](#), [PMID:23887712](#), [PMID:30894373](#), [PMID:31063779](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:32899426](#)

Comments: Population: Japanese., Part of: JFCR45 cancer cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HuH-6

Synonyms: HUH-6, HuH 6, HuH6, HUH6, Huh6

Cross References: BTO:BTO_0001670, CLO:CLO_0050851, ABM:T9914, ArrayExpress:E-MTAB-2770, BioGRID_ORCS_Cell_line:643, BioSample:SAMN10987713, cancercellines:CVCL_4381, CCRID:1101HUM-PUMC000477, CCRID:3101HUMTCHu181, Cell_Model_Passport:SIDM00062, CLS:305092, Cosmic:869168, Cosmic:869279, Cosmic:873714, Cosmic:1187329, Cosmic:1237546, Cosmic:1518228, Cosmic:1622750, Cosmic:2162537, Cosmic:2369478, Cosmic:2771602, DepMap:ACH-000671, FANTOM5_SSTAR:10633-10813,

GEO:GSM887148, GEO:GSM888220, GEO:GSM936762, IARC_TP53:28317, LiGeA:CCLE_149, Progenetix:CVCL_4381, RCB:RCB1367, Wikidata:Q54896848

ID: CVCL_4381

Record Creation Time: 20220427T220622+0000

Record Last Update: 20260815T234259+0000

Ratings and Alerts

No rating or validation information has been found for HuH-6.

No alerts have been found for HuH-6.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 212 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#).

Chen WT, et al. (2026) Functional genomic analysis reveals HAVCR1 as the key regulator of 5q33.3 locus linked to hyperlipidemia. HGG advances, 7(3), 100630.

Daniel Y, et al. (2025) PPAR γ , a key modulator of metabolic reprogramming, stemness and chemoresistance associated with retrodifferentiation in human hepatocellular carcinomas. Cell death & disease, 16(1), 831.

Zhu T, et al. (2025) Endogenous YAP/TAZ partitioning in TEAD condensates orchestrates the Hippo response. Molecular cell.

Rodemann MM, et al. (2025) Identification of a Growth-Promoting Gene Cluster in the Region 2q24 as a Driver of Tumorigenesis in Childhood Hepatoblastoma. The American journal of pathology, 195(8), 1553.

Gritti I, et al. (2025) DNAJB1-PRKACA Fusion Drives Fibrolamellar Liver Cancer through Impaired SIK Signaling and CRTC2/p300-Mediated Transcriptional Reprogramming. Cancer discovery, 15(2), 382.

Pérez-Chávez I, et al. (2024) Tracking fructose 1,6-bisphosphate dynamics in liver cancer cells using a fluorescent biosensor. iScience, 27(12), 111336.

Song M, et al. (2024) DNA of Neutrophil Extracellular Traps Binds TMCO6 to Impair CD8+ T-cell Immunity in Hepatocellular Carcinoma. Cancer research, 84(10), 1613.

- Kong Y, et al. (2023) Lipophagy-mediated cholesterol synthesis inhibition is required for the survival of hepatocellular carcinoma under glutamine deprivation. *Redox biology*, 63, 102732.
- Zhu J, et al. (2023) SNORA14A inhibits hepatoblastoma cell proliferation by regulating SDHB-mediated succinate metabolism. *Cell death discovery*, 9(1), 36.
- Guo T, et al. (2023) Dihydromyricetin functions as a tumor suppressor in hepatoblastoma by regulating SOD1/ROS pathway. *Frontiers in oncology*, 13, 1160548.
- Héraud C, et al. (2023) Identification of an inhibitory domain in GTPase-activating protein p190RhoGAP responsible for masking its functional GAP domain. *The Journal of biological chemistry*, 299(1), 102792.
- Zhou Y, et al. (2023) Sustained activation of EGFR-ERK1/2 signaling limits the response to tigecycline-induced mitochondrial respiratory deficiency in liver cancer. *EBioMedicine*, 87, 104397.
- Gest C, et al. (2023) Antagonism between wild-type and mutant β -catenin controls hepatoblastoma differentiation via fascin-1. *JHEP reports : innovation in hepatology*, 5(5), 100691.
- Tang Y, et al. (2023) β -catenin interaction with YAP/FoxM1/TEAD-induced CEP55 supports liver cancer cell migration. *Cell communication and signaling : CCS*, 21(1), 162.
- Cui Z, et al. (2023) O-GlcNAcylated LARP1 positively regulated by circCLNS1A facilitates hepatoblastoma progression through DKK4/ β -catenin signalling. *Clinical and translational medicine*, 13(4), e1239.
- Nousiainen R, et al. (2023) UBE2C expression is elevated in hepatoblastoma and correlates with inferior patient survival. *Frontiers in genetics*, 14, 1170940.
- Tsuchiya H, et al. (2023) NEAT1-SOD2 Axis Confers Sorafenib and Lenvatinib Resistance by Activating AKT in Liver Cancer Cell Lines. *Current issues in molecular biology*, 45(2), 1073.
- Chen DY, et al. (2023) Cell culture systems for isolation of SARS-CoV-2 clinical isolates and generation of recombinant virus. *iScience*, 26(5), 106634.
- Han Y, et al. (2023) BMP9-induced vascular normalisation improves the efficacy of immunotherapy against hepatitis B virus-associated hepatocellular carcinoma. *Clinical and translational medicine*, 13(5), e1247.
- Eloranta K, et al. (2023) SLC-0111, an inhibitor of carbonic anhydrase IX, attenuates hepatoblastoma cell viability and migration. *Frontiers in oncology*, 13, 1118268.